Tag Archives: Lovenox

FDA Advisory Committee Briefing hits Bayer’s Xarelto® badly.

By Xavier Tello One of the most desired markets of the pharmaceutical business has been the clotting-prevention. Ever since the first use of systemic heparin and the late surging of the low molecular weight heparins (LMWH) such as Lovenox® (enoxaparin), … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Sanofi-Aventis shows 2008 figures and new Top Executive Positions.

Written by Xavier Tello This morning sanofi-aventis has released to the press its financial results for 2008. The results, conservative (as expected) but “above guidance” are shown bellow.   Key comments: 2008 Net Sales: € 27,568 M (+ 3.7%) EPS at €5.49 … Continue reading

Posted in Alta Dirección, Mercadotecnia, Planeac. Estratégica, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment